Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,600.00
Bid: 1,598.00
Ask: 1,598.50
Change: -4.50 (-0.28%)
Spread: 0.50 (0.031%)
Open: 1,613.00
High: 1,613.00
Low: 1,589.00
Prev. Close: 1,604.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET PULSE-Santarus, Sequenom, Durect, Tremor, Gap

Fri, 08th Nov 2013 12:44

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s)

Nov 8 (Reuters) - U.S. stock index futures advanced onFriday, indicating the S&P 500 will rebound from its biggestdaily decline since late August, ahead of a key report on thelabor market. S&P 500 futures was up 3.6 points, DowJones industrial average futures was up 11 points andNasdaq 100 futures was up 12 points.

** TWITTER INC, Thursday close $44.90, up 0.8 pctpremarket

The micro-blogging site's shares jumped 73 percent in afrenzied trading debut that drove the seven-year-old company'smarket value to around $25 billion and evoked the heady days ofthe dot-com bubble.

** SANTARUS INC, Thursday close $, up 37 pct aftermarket

** SALIX PHARMACEUTICALS LTD, Thursday close$71.31, up 9.3 pct after market

Salix said it will buy Santarus for about $2.6 billion,gaining two new gastroenterology drugs to strengthen its leadingpresence in that market.

** SEQUENOM INC, Thursday close $1.70, up 23 pctafter market

The genetic testing company reported a smaller-than-expectedthird-quarter loss on Thursday due to higher sales of itsprenatal test designed to detect fetal chromosomalabnormalities.

** DURECT CORP, Thursday close $1.54, down 20percent after market

The drugmaker said it is offering shares in an underwrittenpublic offering. The company had about 102 million sharesoutstanding as of Thursday.

** INSULET CORP, Thursday close $37.05, down 8 pctafter market

The medical device maker reported a muchbigger-than-expected third-quarter loss on Thursday as operatingexpenses rose due to the settlement of a patent lawsuit withMedtronic Inc and the launch of a version of its insulinmanagement system OmniPod.

** PRICELINE.COM INC, Thursday close $1022.89, up1.6 pct premarket

The online travel agency known for its name-your-own priceauction, posted a higher-than-expected quarterly profit onThursday as bookings increased.

** TREMOR VIDEO INC, Thursday close $9.26, down 30pct after market

The online video advertising provider reportedlower-than-expected third-quarter results on Thursday and cutits revenue forecast for 2013. Canaccord Genuitycuts its rating on the stock to "hold" from "buy" and its pricetarget by $3.50 to $9.

* CHEMOCENTRYX INC, Thursday close $4.67, up 7 pctpremarket

The company reported a smaller-than-expected quarterly lossdue to lower expenses and higher revenue from its partnerGlaxoSmithKline Plc, which is funding Chemocentryx drugto treat a disease that causes inflammation of blood vessels inthe kidney.

** WALT DISNEY CO, Thursday close $67.15

The company reported a 12 percent gain in profit that beatWall Street expectations, lifted by higher visitor spending atU.S. theme parks, increased consumer product sales and itssummer animated movie hit "Monsters University." Shares ofDisney, which have gained nearly 35 percent this year, slipped1.8 percent in after-hours trading to $65.94.

** MOLYCORP INC, Thursday close $4.76

The rare earths producer has seen demand and prices for itsproducts rise from their second-quarter lows, the company'schief executive said on Thursday, although the company reporteda wider third-quarter loss.

** BLACKBERRY LTD , Thursday close $6.5

The company will pay its new interim CEO a base salary of $1million, a bonus of up to twice that amount as well as stockawards potentially worth some $85 million, in the hopes ofturning around Canada's most prominent technology company.

** COCA-COLA CO, Thursday close $40.05

The company said it will invest over $4 billion in China andbuild new plants between 2015 and 2017, to counter competitionwhich is chipping away at its share of the country's 421 billionyuan ($69.12 billion) soft drinks market.

** PIXELWORKS INC, Thursday close $4.39, down 8.8pct after market

The digital display chip maker's third-quarter results camein below analysts' expectations on Thursday due to lower chiprevenue.

** GROUPON INC,Thursday close $9.50, up 1.3 pctpremarket

The daily coupon website reported a third-quarter profitthat beat analysts' estimates as strong growth in North Americahelped offset a decline in international revenue.

** SPROUTS FARMERS MARKET INC, Thursday close$46.58, down 4.8 pct after market

The retailer of natural and organic foods on Thursday saidaffiliates of Apollo Global Management LLC, and certain otherstockholders, will sell up to 22.5 million shares in a secondaryoffering.

** AMARIN CORP, Thursday close $1.41, up 6.3 pctafter market

The drugmaker reported a smaller-than-expected third-quarterloss on Thursday as sales of its fish-oil drug Vascepa, whichlowers a type of blood fat, jumped 52 percent from the secondquarter. Total prescriptions for Vascepa were up 58 percent fromthe preceding quarter, Amarin said in a statement.

** FIREEYE INC, Thursday close $38.03, up 9 pctafter market

The technology firm that helps companies fend off cyberattacks, gave a revenue outlook for 2014 that came in ahead ofWall Street forecasts as it posted results for the first timesince it went public in September in one of this year's hottestIPOs.

** GAP INC, Thursday close $37.75, up 8 pct aftermarket

The apparel chain's October same-store sales rose 4 percent,well ahead of the analysts' average estimate of 0.1 percent.

** ARENA PHARMACEUTICALS INC, Thursday close $4.08,up 5 pct after market

The company said Japanese drugmaker Eisai Co Ltd will market its diet drug in most markets worldwide as part ofan expanded agreement, under which the companies will alsodevelop the drug for other indications.

** TALISMAN ENERGY INC Thursday close $11.71

The company said it would sell a stake in some ofits natural gas assets in British Columbia's Montney field toMalaysia-controlled Progress Energy Canada Ltd for C$1.5 billion($1.44 billion) as it restructures global operations.

** JOHNSON & JOHNSON, Thursday close $92.69

Healthcare conglomerate Danaher Corp DHR.N has teamed upwith Blackstone Group LP BX.N to bid for the company'sdiagnostics unit, which makes blood screening equipment andlaboratory blood tests and could fetch more than $4 billion,according to people familiar with the matter.

** NVIDIA CORP, Thursday close $14.54, up 2 pctafter market

The graphics chipmaker gave a revenue forecast for thecurrent quarter that was shy of Wall Street's expectations asthe company faces tough competition in tablets and a slowpersonal computer market.

** GENCO SHIPPING AND TRADING LTD, Thursday close$2.66, down 2.2 pct after market

Analysts at Wells Fargo Securities said the dry bulkshipper, which has short-term debt of $1.5 billion, was likelyto breach its debt agreements. "It remains increasingly unlikelythat Genco Shipping will be able to maintain covenant compliancethrough March 31, 2014," analyst Michael Webber said.

** COSTA INC, Thursday close $19.98

Essilor International said it would buy Costa, amaker of premium sport sunglasses, in a $270 million deal thatwould help the French company tap into the growing prescriptionsun lens market.

(Compiled by Natalie Grover; Editing by Don Sebastian)

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.